SeaStar Medical Holding Corp (ICU) Form 10-Q — May 13, 2026
SeaStar Medical Holding Corporation reported a net loss of $3.5 million for the three months ended March 31, 2026, compared to a net loss of $3.8 million for the same period in 2025. The company's revenue increased by 69% to $0.5 million, driven by increased customer adoption of its commercialized product, QUELIMMUNE. The company has an accumulated deficit of $155.2 million as of March 31, 2026, and a cash position of $9.3 million. The company's financial statements are prepared on a going concern basis, but substantial doubt exists about its ability to continue as a going concern due to recurring losses and limited cash reserves.
Key figures
- Revenue
- 495
- Total Debt
- 331
- Revenue Yoy
- 69
- Cash Position
- 9348
Price after filing
Close on the filing date to close N calendar days later (from $4.60). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.